Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
NCT ID: NCT01919450
Last Updated: 2018-08-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2013-07-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress
NCT00808314
3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
NCT05286593
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
NCT01334918
Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET
NCT01109992
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
NCT03103061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10 Second Delay
A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
Regadenoson
Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Rubidium-82
Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
2 Minute Delay
A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
Regadenoson
Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Rubidium-82
Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
4 Minute Delay
A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
Regadenoson
Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Rubidium-82
Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
1 Minute Delay
A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
Regadenoson
Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Rubidium-82
Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Regadenoson
Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Rubidium-82
Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No change in symptoms between the exercise study and PET study
* Capable of providing written informed consent
* BMI 25-32 kg/m2
Exclusion Criteria
* Coronary Artery Calcium Score \>25
* Second and Third Degree Atrioventricular Node Block
* Sinus Node Dysfunction
* Recent Syncope of unknown etiology
* Left ventricular hypertrophy per ECG or echocardiography
* Slowed circulation times
* Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes in therapy within the past 30 days.
* Patients that have experienced a previous hypersensitivity reaction thought to be related to Lexiscan
40 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Timothy M. Bateman, MD
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Timothy M. Bateman, MD
Medical Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy M Bateman, MD
Role: PRINCIPAL_INVESTIGATOR
Cardiovascular Imaging Technologies
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Luke's Hospital Imaging Center
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.